Johns Hopkins graduate students have invented a system to significantly boost the number of stem cells collected from a newborn's umbilical cord and placenta, so that many more patients with leukemia, lymphoma and other blood disorders can be treated with these valuable cells.

The prototype is still in the testing stage, but initial results are promising. The student inventors have obtained a provisional patent covering the technology and have formed a company, TheraCord LLC, to further develop the technology, which may someday be used widely in hospital maternity units. The students say the need for this system is obvious.

"Cord blood, collected from the umbilical cord and placenta after live birth, is the most viable source of stem cells, yet over 90 percent is uncollected and discarded," the team members wrote in a presentation of their project at the university's recent Biomedical Engineering Design Day. "One of the main reasons valuable cord blood is so frequently discarded is because no adequate collection method exists."

The students say their easy-to-use invention, called the CBx System, could remedy these shortcomings.

Source: Johns Hopkins University